MX2024007317A - Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular. - Google Patents

Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular.

Info

Publication number
MX2024007317A
MX2024007317A MX2024007317A MX2024007317A MX2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A
Authority
MX
Mexico
Prior art keywords
surface protein
discernible
therapy
protein variants
cell
Prior art date
Application number
MX2024007317A
Other languages
English (en)
Inventor
Stefanie Urlinger
Rosalba Lepore
Marone Romina Matter
Lukas Jeker
Amélie Wiederkehr
Alessandro Sinopoli
Anna Camus
Lisa Wellinger
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of MX2024007317A publication Critical patent/MX2024007317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere al uso de células que tienen proteína de superficie discernible con mutación(es) diseñada(s) o de origen natural, pero proteína de superficie funcional para usarse en terapia. La presente invención también se refiere al uso de células que tienen variantes discernibles de proteína de superficie CD117, pero proteína de superficie funcional para usarse en terapia, en particular en terapia celular adoptiva.
MX2024007317A 2021-12-16 2022-12-16 Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular. MX2024007317A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21215028 2021-12-16
EP22164796 2022-03-28
EP22207926 2022-11-16
PCT/EP2022/086452 WO2023111311A1 (en) 2021-12-16 2022-12-16 Discernible cell surface protein variants of cd117 for use in cell therapy

Publications (1)

Publication Number Publication Date
MX2024007317A true MX2024007317A (es) 2024-06-26

Family

ID=84981434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007317A MX2024007317A (es) 2021-12-16 2022-12-16 Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular.

Country Status (7)

Country Link
EP (1) EP4448573A1 (es)
KR (1) KR20240115920A (es)
AU (1) AU2022409748A1 (es)
CA (1) CA3240527A1 (es)
IL (1) IL313568A (es)
MX (1) MX2024007317A (es)
WO (1) WO2023111311A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023248126A1 (en) * 2022-06-20 2023-12-28 Crispr Therapeutics Ag Chimeric antigen receptor specific to cd117
WO2024008910A1 (en) * 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3213314B2 (ja) 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
EP3448995A1 (en) 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
JP7305539B2 (ja) 2016-11-02 2023-07-10 ウニベルシテート バーゼル 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体
MX2019010196A (es) 2017-02-28 2019-12-19 Vor Biopharma Inc Composiciones y métodos para la inhibición de proteínas específicas del linaje.
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
TW201922782A (zh) * 2017-10-24 2019-06-16 美商麥珍塔治療學股份有限公司 去除cd117+細胞之組合物及方法
CN111372608B (zh) 2017-10-24 2024-07-02 克里斯珀医疗股份公司 用于耗尽cd117+细胞的组合物和方法
BR112021002276A2 (pt) * 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
PE20211786A1 (es) 2018-11-26 2021-09-09 Forty Seven Inc Anticuerpos humanizados contra c-kit
WO2020219748A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibodies and uses thereof
AU2020336969A1 (en) 2019-08-29 2022-03-03 Beam Therapeutics Inc. Compositions and methods for non-toxic conditioning

Also Published As

Publication number Publication date
KR20240115920A (ko) 2024-07-26
CA3240527A1 (en) 2023-06-22
IL313568A (en) 2024-08-01
AU2022409748A1 (en) 2024-05-23
WO2023111311A1 (en) 2023-06-22
EP4448573A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
MX2024007317A (es) Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular.
MX2024010824A (es) Moleculas de union contra bcma y usos de las mismas.
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
WO2019035880A8 (en) EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
WO2018097540A3 (ko) 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물
SG148171A1 (en) Methods of proliferating stem cells
GB2454386A (en) Method for stem cell culture and cells derived therefrom
NZ703148A (en) Modified factor x polypeptides and uses thereof
MX2008007286A (es) Ingenieria in vivo de superficie celular.
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
DE60103052D1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
MX2011011402A (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX366018B (es) Composiciones de células t deficientes del receptor de células t.
NZ600585A (en) Expression of hexose kinase in recombinant host cells
WO2011096728A3 (en) Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling
MX2023006456A (es) Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos.
DOP2014000294A (es) Purificación de iduronato 2 sulfatasa
IN2014DN11272A (es)
MX2022004345A (es) Construcciones de igf2 variantes.
MX2024007316A (es) Variantes discernibles de proteina de superficie celular de cd45 para usarse en terapia celular.
NZ609594A (en) Eph receptor expression in tumor stem cells
WO2006102209A3 (en) Cd34(+) cells and their methods of use
WO2006047743A3 (en) Swine multipotent adult progenitor cells
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof